Vivos Therapeutics appoints Baker Tilly as independent auditor after Moss Adams merger

Vivos Therapeutics, Inc.

Moss Adams merged into Baker Tilly effective June 3, 2025; Moss Adams resigned as auditor.
Audit committee approved Baker Tilly as successor independent registered public accounting firm.
No disagreements or reportable events between Vivos and Moss Adams during 2023, 2024, or through June 3, 2025.
Moss Adams' prior audit reports contained an explanatory paragraph regarding going concern uncertainty.
No consultations with Baker Tilly on accounting principles or disagreements occurred before appointment.

item 4.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.